Field Guide to Challenges and Opportunities in Antibody-Drug Conjugates for Chemists

Bioconjugate Chemistry

Volumn 26, Issue 11, 2015, Pages 2198-2215

  Gordon, Mallory R ^a   Canakci, Mine ^a   Li, Longyu ^a   Zhuang, Jiaming ^a   Osborne, Barbara ^a   Thayumanavan, S ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES;

ANTIBODY-DRUG CONJUGATES; CANCER THERAPY; CELL-BE; CELL/B.E; CELL/BE; CRITICAL COMPONENT; DESIGN CHALLENGES; RESEARCH AND DEVELOPMENT; STABILITY REQUIREMENTS; THERAPEUTIC STRATEGY;

DISEASE CONTROL;

ANTIBODY; BRENTUXIMAB VEDOTIN; CALICHEAMICIN; CAPECITABINE; DOXORUBICIN; GEMTUZUMAB OZOGAMICIN; HYDRAZINE DERIVATIVE; LAPATINIB; METHOTREXATE; MONOCLONAL ANTIBODY; NANOPARTICLE; SIALIC ACID; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; VINBLASTINE; ANTIBODY CONJUGATE;

ACUTE MYELOBLASTIC LEUKEMIA; ANTIBODY STRUCTURE; CANCER THERAPY; CYTOTOXICITY; DRUG CONJUGATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LIVER TOXICITY; NONHUMAN; OXIDATION REDUCTION REACTION; PH; REVIEW; STOICHIOMETRY; ANIMAL; BIOCATALYSIS; CHEMISTRY; MOLECULAR MODEL; PROCEDURES; SYNTHESIS;

ANIMALS; BIOCATALYSIS; CHEMISTRY TECHNIQUES, SYNTHETIC; HUMANS; IMMUNOCONJUGATES; MODELS, MOLECULAR; NANOPARTICLES;

EID: 84947770168     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/acs.bioconjchem.5b00399     Document Type: Review

References (119)

1. American Cancer Society. Cancer Facts & Figures 2015. American Cancer Society, Atlanta; 2015.
2. Frei, E., III. (1972) Combination Cancer Therapy: Presidential Address Cancer Res. 32, 2593-2607
3. Chari, R. V. J., Miller, M. L., and Widdison, W. C. (2014) Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy Angew. Chem., Int. Ed. 53, 3796-3827 10.1002/anie.201307628
4. Ehrlich, P. (1897) Zur Kenntis der Antitoxinwirkung Forschritte der Medizin. 14, 41-43
5. Kratz, F., Muller, I. A., Ryppa, C., and Warnecke, A. (2008) Prodrug strategies in anticancer chemotherapy ChemMedChem 3, 20-53 10.1002/cmdc.200700159
6. Panchal, R. G. (1998) Novel therapeutic strategies to selectively kill cancer cells Biochem. Pharmacol. 55, 247-252 10.1016/S0006-2952(97)00240-2
7. Zangemeister-Wittke, U. (2005) Antibodies for targeted cancer therapy- technical aspects and clinical perspectives Pathobiology 72, 279-286 10.1159/000091325
8. Tolcher, A. W., Sugarman, S., Gelmon, K. A., Cohen, R., Saleh, M., Isaacs, C., Young, L., Healey, D., Onetto, N., and Slichenmyer, W. (1999) Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer J. Clin. Oncol. 17 (2) 478-484
9. Trail, P. A., Willner, D., Lasch, S. J., Henderson, A. J., Hofstead, S., Casazza, A. M., Firestone, R. A., Hellström, I., and Hellström, K. E. (1993) Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates Science 261, 212-215 10.1126/science.8327892
10. Chari, R. V. (2008) Targeted cancer therapy: conferring specificity to cytotoxic drugs Acc. Chem. Res. 41, 98-107 10.1021/ar700108g
11. Schmidt, M. M. and Wittrup, K. D. (2009) A modeling analysis of the effects of molecular size and binding affinity on tumor targeting Mol. Cancer Ther. 8, 2861-2871 10.1158/1535-7163.MCT-09-0195
12. Lencer, W. I. and Blumberg, R. S. (2005) A passionate kiss, then run: exocytosis and recycling of IgG by FcRn Trends Cell Biol. 15, 5-9 10.1016/j.tcb.2004.11.004
13. Alley, S. C., Okeley, N. M., and Senter, P. D. (2010) Antibody-drug conjugates: targeted drug delivery for cancer Curr. Opin. Chem. Biol. 14, 529-537 10.1016/j.cbpa.2010.06.170
14. Ducry, L. and Stump, B. (2010) Antibody-Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies Bioconjugate Chem. 21, 5-13 10.1021/bc9002019
15. Ho, R. J. Y. and Chien, J. (2014) Trends in Translational Medicine and Drug Targeting and Delivery: New Insights on an Old Concept-Targeted Drug Delivery with Antibody-Drug Conjugates for Cancers J. Pharm. Sci. 103, 71-77 10.1002/jps.23761
16. Perez, H. L., Cardarelli, P. M., Deshpande, S., Gangwar, S., Schroeder, G. M., Vite, G. D., and Borzilleri, R. M. (2014) Antibody-drug conjugates: current status and future directions Drug Discovery Today 19, 869-881 10.1016/j.drudis.2013.11.004
17. Panowski, S., Bhakta, S., Raab, H., Polakis, P., and Junutula, J. R. (2014) Site-specific antibody drug conjugates for cancer therapy mAbs. 6, 34-45 10.4161/mabs.27022
18. Cal, P. M. S. D., Bernarder, G. J. L., and Gois, P. M. P. (2014) Cysteine-Selective Reactions for Antibody Conjugation Angew. Chem., Int. Ed. 53, 2-5 10.1002/anie.201405702
19. Agarwal, P. and Bertozzi, C. R. (2015) Site-Specific Antibody-Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development Bioconjugate Chem. 26, 176-192 10.1021/bc5004982
20. Merten, H., Brandl, F., Plückthun, A., and Zangemeister-Wittke, U. (2015) Antibody drug conjugates for tumor targeting-novel conjugation chemistries and the promise of non-IgG binding proteins Bioconjugate Chem. 10.1021/acs.bioconjchem.5b00260
21. Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Guearing, R. P., Bovee, T. D., and Siegall, C. B. et al. 2003, Development of potent monoclonal antibody auristatin conjugates for cancer therapy Nat. Biotechnol. 21, 778-784 10.1038/nbt832
22. Wakankar, A., Chen, Y., Gokarn, Y., and Jacobson, F. S. (2011) Analytical methods for physicochemical characterization of antibody drug conjugates MAbs. 3, 161-172 10.4161/mabs.3.2.14960
23. Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., and Zabinski, R. F. et al. 2004, Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate Clin. Cancer Res. 10, 7063-7070 10.1158/1078-0432.CCR-04-0789
24. Doronina, S. O., Mendelsohn, B. A., Bovee, T. D., Cerveny, C. G., Alley, S. C., Meyer, D. L., Oflazoglu, E., Toki, B. E., Sanderson, R. J., and Zabinski, R. F. et al. 2006, Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity Bioconjugate Chem. 17, 114-124 10.1021/bc0502917
25. Baldwin, A. D. and Kiick, K. L. (2011) Tunable degradation of maleimide-thiol adducts in reducing environments Bioconjugate Chem. 22, 1946-1953 10.1021/bc200148v
26. Shen, B.-Q., Xu, K., Liu, L., Raab, H., Bhakta, S., Kenrick, M., Parsons-Reponte, K. L., Tien, J., Yu, S.-F., and Mai, E. et al. 2012, Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates Nat. Biotechnol. 30, 184-189 10.1038/nbt.2108
27. Smith, M. E. B., Schumacher, F. F., Ryan, C. P., Tedaldi, L. M., Papaioannou, D., Waksman, G., Caddick, S., and Baker, J. R. (2010) Protein Modification, Bioconjugation, and Disulfide Bridging Using Bromomaleimides J. Am. Chem. Soc. 132, 1960-1965 10.1021/ja908610s
28. Masri, M. S. and Friedman, M. (1988) Protein reactions with methyl and ethyl vinyl sulfones J. Protein Chem. 7, 49-54 10.1007/BF01025413
29. Abbas, A., Xing, B., and Loh, T.-P. (2014) Allenamides as Orthogonal Handles for Selective Modification of Cysteine in Peptides and Proteins Angew. Chem., Int. Ed. 53, 7491-7494 10.1002/anie.201403121
30. Bernardes, G. J. L., Chalker, J. M., Errey, J. C., and Davis, B. G. (2008) Facile Conversion of Cysteine and Alkyl Cysteines to Dehydroalanine on Protein Surfaces: Versatile and Switchable Access to Functionalized Proteins J. Am. Chem. Soc. 130, 5052-5053 10.1021/ja800800p
31. Li, F., Allahverdi, A., Yang, R., Lua, G. B. J., Zhang, X., Cao, Y., Korolev, N., Nordenskiold, L., and Liu, C.-F. (2011) A Direct Method for Site-Specific Protein Acetylation Angew. Chem., Int. Ed. 50, 9611-9614 10.1002/anie.201103754
32. NAr Chemistry Approach to Unprotected Peptide Stapling J. Am. Chem. Soc. 135, 5946-5949 10.1021/ja400119t
33. Toda, N., Asano, S., and Barbas, C. F. (2013) Rapid, Stable, Chemoselective Labeling of Thiols with Julia-Kocienski-like Reagents: A Serum-Stable Alternative to Maleimide-Based Protein Conjugation Angew. Chem., Int. Ed. 52, 12592-12596 10.1002/anie.201306241
34. Badescu, G., Bryant, P., Bird, M., Henseleit, K., Swierkosz, J., Parekh, V., Tommasi, R., Pawlisz, E., Jurlewicz, K., and Farys, M. et al. 2014, Bridging Disulfides for Stable and Defined Antibody Drug Conjugates Bioconjugate Chem. 25, 1124-1136 10.1021/bc500148x
35. McDonagh, C. F., Turcott, E., Westendorf, L., Webster, J. B., Alley, S. C., Kim, K., Andreyka, J., Stone, I., Hamblett, K. J., and Francisco, J. A. et al. 2006, Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment Protein Eng., Des. Sel. 19, 299-307 10.1093/protein/gzl013
36. Kim, M. T., Chen, Y., Marhoul, J., and Jacobson, F. (2014) Statistical Modeling of the Drug Load Distribution on Trastuzumab Emtansine (Kadcyla), a Lysine-Linked Antibody Drug Conjugate Bioconjugate Chem. 25, 1223-1232 10.1021/bc5000109
37. Sako, Y., Minoguchi, S., and Yanagida, T. (2000) Single- molecule imaging of EGFR signalling on the surface of living cells Nat. Cell Biol. 2, 168-172 10.1038/35004044
38. Vira, S., Mekhedov, E., Humphrey, G., and Blank, P. S. (2010) Fluorescent-labeled antibodies: Balancing functionality and degree of labeling Anal. Biochem. 402, 146-150 10.1016/j.ab.2010.03.036
39. Bross, P. F., Beitz, J., Chen, G., Chen, X. H., Duffy, E., Kieffer, L., Roy, S., Sridhara, R., Rahman, A., and Williams, G. et al. 2001, Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia Clin. Cancer Res. 7, 1490-1496
40. Bender, B., Leipold, D. D., Xu, K., Shen, B. Q., Tibbitts, J., and Friberg, L. E. (2014) A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer AAPS J. 16, 994-1008 10.1208/s12248-014-9618-3
41. Carlsson, J., Drevin, H., and Axen, R. (1978) Protein thiolation and reversible protein-protein conjugation. N-Succinimidyl 3-(2-pyridyldithio)propionate, a new heterobifunctional reagent Biochem. J. 173, 723-737 10.1042/bj1730723
42. Thorpe, P. E., Wallace, P. M., Knowles, P. P., Relf, M. G., Brown, A. N., Watson, G. J., Knyba, R. E., Wawrzynczak, E. J., and Blakey, D. C. (1987) New Coupling Agents for the Synthesis of Immunotoxins Containing a Hindered Disulfide Bond with Improved Stability in Vivo Cancer Res. 47, 5924-5931
43. Duncan, R. J. S., Weston, P. D., and Wrigglesworth, R. (1983) A new reagent which may be used to introduce sulfhydryl groups into proteins, and its use in the preparation of conjugates for immunoassay Anal. Biochem. 132, 68-73 10.1016/0003-2697(83)90426-8
44. Talelli, M., Rijcken, C. J., Oliveira, S., van der Meel, R., van Bergen en Henegouwen, P. M., Lammers, T., van Nostrum, C. F., Storm, G., and Hennink, W. E. (2011) Nanobody-Shell functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting J. Controlled Release 151, 183-192 10.1016/j.jconrel.2011.01.015
45. Fujii, N., Akaji, K., Hayashi, Y., and Yajima, H. (1985) Studies on Peptides. CXXV. 3-(3-p-Methoxybenzylthiopropionyl)-thiazolidine-2-thione and Its Analogs as Reagents for the Introduction of the Mercapto Group into Peptides and Proteins Chem. Pharm. Bull. 33, 362-367 10.1248/cpb.33.362
46. Klotz, I. M. and Heiney, R. E. (1962) Introduction of sulfhydryl groups into proteins using acetylercaptosuccinic anhydride Arch. Biochem. Biophys. 96, 605-612 10.1016/0003-9861(62)90345-4
47. Witus, L. S., Netirojjanakul, C., Palla, K. S., Muehl, E. M., Weng, C.-H., Iavarone, A. T., and Francis, M. B. (2013) Site-Specific Protein Transamination Using N-Methylpyridinium-4-carboxaldehyde J. Am. Chem. Soc. 135, 17223-17229 10.1021/ja408868a
48. Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., and Dennis, M. S. et al. 2008, Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index Nat. Biotechnol. 26, 925-932 10.1038/nbt.1480
49. Chumsae, C., Gaza-Bulseco, G., and Liu, H. (2009) Identification and localization of unpaired cysteine residues in monoclonal antibodies by fluorescence labeling and mass spectrometry Anal. Chem. 81, 6449-6457 10.1021/ac900815z
50. Junutula, J. R., Bhakta, S., Raab, H., Ervin, K. E., Eigenbrot, C., Vandlen, R., Scheller, R. H., and Lowman, H. B. (2008) Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs J. Immunol. Methods 332, 41-52 10.1016/j.jim.2007.12.011
51. Junutula, J. R., Flagella, K. M., Graham, R. A., Parsons, K. L., Ha, E., Raab, H., Bhakta, S., Nguyen, T., Dugger, D. L., and Li, G. et al. 2010, Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer Clin. Cancer Res. 16, 4769-7478 10.1158/1078-0432.CCR-10-0987
52. Boswell, C. A., Mundo, E. E., Zhang, C., Bumbaca, D., Valle, N. R., Kozak, K. R., Fourie, A., Chuh, J., Koppada, N., and Saad, O. et al. 2011, Impact of Drug Conjugation on Pharmacokinetics and Tissue Distribution of Anti-STEAP1 Antibody-Drug Conjugates in Rats Bioconjugate Chem. 22, 1994-2004 10.1021/bc200212a
53. Jeffrey, S. C., Burke, P. J., Lyon, R. P., Meyer, D. W., Sussman, D., Anderson, M., Hunter, J. H., Leiske, C. I., Miyamoto, J. B., and Nicholas, N. D. et al. 2013, A Potent Anti-CD70 Antibody-Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology Bioconjugate Chem. 24, 1256-1263 10.1021/bc400217g
54. Axup, J. Y., Bajjuri, K. M., Ritland, M., Hutchins, B. M., Kim, C. H., Kazane, S. A., Halder, R., Forsyth, J. S., Santidrian, A. F., and Stafin, K. et al. 2012, Synthesis of site-specific antibody-drug conjugates using unnatural amino acids Proc. Natl. Acad. Sci. U. S. A. 109, 16101-16106 10.1073/pnas.1211023109
55. Rodwell, J. D., Alvarez, V. L., Lee, C., Lopes, A. D., Goers, J. W. F., King, H. D., Powsner, H. J., and McKearn, T. J. (1986) Site-specific covalent modification of monoclonal antibodies: In vitro and in vivo evaluations Proc. Natl. Acad. Sci. U. S. A. 83, 2632-2636 10.1073/pnas.83.8.2632
56. Zuberbuhler, K., Casi, G., Bernardes, G. J. L., and Neri, D. (2012) Fucose-specific conjugation of hydrazide derivatives to a vascular-targeting monoclonal antibody in IgG format Chem. Commun. 48, 7100-7102 10.1039/c2cc32412a
57. Rabuka, D., Rush, J. S., deHart, G. W., Wu, P., and Bertozzi, C. R. (2012) Site-specific chemical protein conjugation using genetically encoded aldehyde tags Nat. Protoc. 7, 1052-1067 10.1038/nprot.2012.045
58. Sasaki, T., Kodama, K., Suzuki, H., Fukuzawa, S., and Tachibana, K. (2008) N-terminal labeling of proteins by the Pictet-Spengler reaction Bioorg. Med. Chem. Lett. 18, 4550-4553 10.1016/j.bmcl.2008.07.033
59. Maresh, J. J., Giddings, L.-A, Friedrich, A., Loris, E. A., Panjikar, S., Trout, B. L., Stockigt, J., Peters, B., and O'Connor, S. E. (2008) Strictosidine Synthase- Mechanism of a Pictet-Spengler Catalyzing Enzyme J. Am. Chem. Soc. 130, 710-723 10.1021/ja077190z
60. Agarwal, P., van der Weijden, J., Sletten, E. M., Rabuka, D., and Bertozzi, C. R. (2013) A Pictet-Spengler ligation for protein chemical modification Proc. Natl. Acad. Sci. U. S. A. 110, 46-51 10.1073/pnas.1213186110
61. Agarwal, P., Kudirka, R., Albers, A. E., Barfield, R. M., de Hart, G. W., Drake, P. M., Jones, L. C., and Rabuka, D. (2013) Hydrazino-Pictet-Spengler Ligation as a Biocompatible Method for the Generation of Stable Protein Conjugates Bioconjugate Chem. 24, 846-851 10.1021/bc400042a
62. Vaccaro, C., Zhou, J., Ober, R. J., and Ward, E. S. (2005) Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels Nat. Biotechnol. 23, 1283-1288 10.1038/nbt1143
63. Zhou, Q., Stefano, J. E., Manning, C., Kyazike, J., Chen, B., Gianolio, D. A., Park, A., Busch, M., Bird, J., and Zheng, X. et al. 2014, Site-Specific Antibody-Drug Conjugation through Glycoengineering Bioconjugate Chem. 25, 510-520 10.1021/bc400505q
64. Shade, K.-T. and Anthony, R. (2013) Antibody Glycosylation and Inflammation Antibodies 2, 392-414 10.3390/antib2030392
65. Okeley, N. M., Toki, B. E., Zhang, X., Jeffrey, S. C., Burke, P. J., Alley, S. C., and Senter, P. D. (2013) Metabolic Engineering of Monoclonal Antibody Carbohydrates for Antibody-Drug Conjugation Bioconjugate Chem. 24, 1650-1655 10.1021/bc4002695
66. Strop, P., Liu, S.-H., Dorywalska, M., Delaria, K., Dushin, R. G., Tran, T.-T., Ho, W.-H., Farias, S., Casas, M. G., and Abdiche, Y. et al. 2013, Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates Chem. Biol. 20, 161-167 10.1016/j.chembiol.2013.01.010
67. Dennler, P., Chiotellis, A., Fischer, E., Bregeon, D., Belmant, C., Gauthier, L., LhospicE, F., Romagne, F., and Schibli, R. (2014) Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates Bioconjugate Chem. 25, 569-78 10.1021/bc400574z
68. Jeger, S., Zimmermann, K., Blanc, A., Grünberg, J., Honer, M., Hunziker, P., Struthers, H., and Schibli, R. (2010) Angew. Chem., Int. Ed. 49, 9995-9997 10.1002/anie.201004243
69. Elias, D. J., Kline, L. E., Robbins, B. A., Johnson, H. C., Jr., Pekny, K., Benz, M., Robb, J. A., Walker, L. E., Kosty, M., and Dillman, R. O. (1994) Monoclonal antibody KS1/4-methotrexate immunoconjugate studies in non-small cell lung carcinoma Am. J. Respir. Crit. Care Med. 150, 1114-1122 10.1164/ajrccm.150.4.7921445
70. Schneck, D., Butler, F., Dugan, W., Littrell, D., Petersen, B., Bowsher, R., DeLong, A., and Dorrbecker, S. (1990) Disposition of a murine monoclonal antibody vinca conjugate (KS1/4-DAVLB) in patients with adenocarcinomas Clin. Pharmacol. Ther. 47, 36-41 10.1038/clpt.1990.5
71. Petersen, B. H., DeHerdt, S. V., Schneck, D. W., and Bumol, T. F. (1991) The Human Immune Response to KSl/4-Desacetylvinblastine (LY256787) and KSl/4-Desacetylvinblastine Hydrazide (LY203728) in Single and Multiple Dose Clinical Studies Cancer Res. 51, 2286-2290
72. Hamann, P. R., Hinman, L. M., Hollander, I., Beyer, C. F., Lindh, D., Holcomb, R., Hallett, W., Tsou, H. R., Upeslacis, J., and Shochat, D. et al. 2002, Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia Bioconjugate Chem. 13, 47-58 10.1021/bc010021y
73. Boghaert, E. R., Khandke, K. M., Sridharan, L., Dougher, M., DiJoseph, J. F., Kunz, A., Hamann, P. R., Moran, J., Chaudhary, I., and Damle, N. K. (2008) Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 microl) blood samples Cancer Chemother. Pharmacol. 61, 1027-1035 10.1007/s00280-007-0560-2
74. Hamann, P. R., Hinman, L. M., Beyer, C. F., Lindh, D., Upeslacis, J., Flowers, D. A., and Bernstein, I. (2002) An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker Bioconjugate Chem. 13, 40-46 10.1021/bc0100206
75. Hamann, P. R., Hinman, L. M., Beyer, C. F., Lindh, D., Upeslacis, J., Shochat, D., and Mountain, A. (2005) A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts Bioconjugate Chem. 16, 354-360 10.1021/bc049794n
76. Larson, R. A., Boogaerts, M., Estey, E., Karanes, C., Stadtmauer, E. A., Sievers, E. L., Mineur, P., Bennett, J. M., Berger, M. S., and Eten, C. B. et al. 2002, Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin) Leukemia 16, 1627-1636 10.1038/sj.leu.2402677
77. Burnett, A. K., Hills, R. K., Milligan, D., Kjeldsen, L., Kell, J., Russell, N. H., Yin, J. A., Hunter, A., Goldstone, A. H., and Wheatley, K. (2011) Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: Results of the MRC AML15 trial J. Clin. Oncol. 29, 369-377 10.1200/JCO.2010.31.4310
78. Castaigne, S., Pautas, C., Terre, C., Raffoux, E., Bordessoule, D., Bastie, J. N., Legrand, O., Thomas, X., Turlure, P., and Reman, O. et al. 2012, Effect of gemtuzumab ozogamicin on survival of adult patients with de- novo acute myeloid leukaemia (ALFA-0701): A randomised, open-label, phase 3 study Lancet 379, 1508-1516 10.1016/S0140-6736(12)60485-1
79. Wu, G., Fang, Y. Z., Yang, S., Lupton, J. R., and Turner, N. D. (2004) Glutathione metabolism and its implications for health J. Nutr. 134, 489-492
80. Mills, B. J. and Lang, C. A. (1996) Differential distribution of free and bound glutathione and cyst(e)ine in human blood Biochem. Pharmacol. 52, 401-406 10.1016/0006-2952(96)00241-9
81. Kellogg, B. A., Garrett, L., Kovtun, Y., Lai, K. C., Leece, B., Miller, M., Payne, G., Steeves, R., Whiteman, K. R., and Widdison, W. et al. 2011, Disulfide-Linked Antibody-Maytansinoid Conjugates- Optimization of In Vivo Activity by Varying the Steric Hindrance at Carbon Atoms Adjacent to the Disulfide Linkage Bioconjugate Chem. 22, 717-727 10.1021/bc100480a
82. Widdison, W. C., Wilhelm, S. D., Cavanagh, E. E., Whiteman, K. R., Leece, B. A., Kovtun, Y., Goldmacher, V. S., Xie, H., Steeves, R. M., and Lutz, R. J. et al. 2006, Semisynthetic Maytansine Analogues for the Targeted Treatment of Cancer J. Med. Chem. 49, 4392-4408 10.1021/jm060319f
83. Phillips, G. D. L., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., and Lutz, R. J. et al. 2008, Targeting HER2- positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate Cancer Res. 68, 9280-9290 10.1158/0008-5472.CAN-08-1776
84. Erickson, H. K., Park, P. U., Widdison, W. C., Kovtun, Y. V., Garrett, L. M., Hoffman, K., Lutz, R. J., Goldmacher, V. S., and Blättler, W. A. (2006) Antibody-Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by Lysosomal Degradation and Linker-Dependent Intracellular Processing Cancer Res. 66, 4426-4433
85. Kovtun, Y. V., Audette, C. A., Mayo, M. F., Jones, G. E., Doherty, H., Maloney, E. K., Erickson, H. K., Sun, X., Wilhelm, S., and Ab, O. et al. 2010, Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance Cancer Res. 70, 2528-2537 10.1158/0008-5472.CAN-09-3546
86. Kelly, R. K., Olson, D. L., Sun, Y., Wen, D., Wortham, K. A., Antognetti, G., Cheung, A. E., Orozco, O. E., Yang, L., and Bailly, V. et al. 2011, An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours Eur. J. Cancer 47, 1736-1746 10.1016/j.ejca.2011.02.023
87. Erickson, H. K., Phillips, G. D. L., Leipold, D. D., Provenzano, C. A., Mai, E., Johnson, H. A., Gunter, B., Audette, C. A., Gupta, M., and Pinkas, J. et al. 2012, The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates Mol. Cancer Ther. 11, 1133-1142 10.1158/1535-7163.MCT-11-0727
88. Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V., and Lutz, R. J. et al. 2008, Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate Cancer Res. 68, 9280-9290 10.1158/0008-5472.CAN-08-1776
89. Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D. Y., Dieras, V., and Guardino, E. et al. 2012, Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer N. Engl. J. Med. 367, 1783-1791 10.1056/NEJMoa1209124
90. Burris, H. A., III, Rugo, H. S., Vukelja, S. J., Vogel, C. L., Borson, R. A., Limentani, S., Tan-Chiu, E., Krop, I. E., Michaelson, R. A., and Girish, S. et al. 2011, Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy J. Clin. Oncol. 29, 398-405 10.1200/JCO.2010.29.5865
91. Dubowchik, G. M., Mosure, K., Knipe, J. O., and Firestone, R. A. (1998) Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol®), mitomycin C and doxorubicin Bioorg. Med. Chem. Lett. 8, 3347-3352 10.1016/S0960-894X(98)00610-6
92. Sun, M. M., Beam, K. S., Cerveny, C. G., Hamblett, K. J., Blackmore, R. S., Torgov, M. Y., Handley, F. G., Ihle, N. C., Senter, P. D., and Alley, S. C. (2005) Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides Bioconjugate Chem. 16, 1282-1290 10.1021/bc050201y
93. Younes, A., Bartlett, N. L., Leonard, J. P., Kennedy, D. A., Lynch, C. M., Sievers, E. L., and Forero-Torres, A. (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas N. Engl. J. Med. 363, 1812-1821 10.1056/NEJMoa1002965
94. Senter, P. D. and Sievers, E. L. (2012) The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma Nat. Biotechnol. 30, 631-637 10.1038/nbt.2289
95. Younes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., Ramchandren, R., Bartlett, N. L., Cheson, B. D., and de Vos, S. et al. 2012, Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma J. Clin. Oncol. 30, 2183-2189 10.1200/JCO.2011.38.0410
96. Bernardes, G. J. L., Casi, G., Hartmann, I., Trüssel, S., Schwager, K., Scheuermann, J., and Neri, D. (2012) A traceless vascular-targeting antibody-drug conjugate for cancer therapy Angew. Chem., Int. Ed. 51, 941-944 10.1002/anie.201106527
97. Casi, G., Huguenin-Dezot, N., Zuberbuhler, K., Scheuermann, J., and Neri, D. (2012) Site-Specific Traceless Coupling of Potent Cytotoxic Drugs to Recombinant Antibodies for Pharmacodelivery J. Am. Chem. Soc. 134, 5887-5892 10.1021/ja211589m
98. Roopenian, D. C. and Akilesh, S. (2007) FcRn: the neonatal Fc receptor comes of age Nat. Rev. Immunol. 7, 715-725 10.1038/nri2155
99. Yokota, T., Milenic, D. E., Whitlow, M., and Schlom, J. (1992) Rapid Tumor Penetration of a Single-Chain Fv and Comparison with Other Immunoglobulin Forms Cancer Res. 52, 3402-3408
100. Muchekehu, R., Liu, D., Horn, M., Campbell, L., Del Rosario, J., Bacica, M., Moskowitz, H., Osothprarop, T., Dirksen, A., and Doppalapudi, V. et al. 2013, The Effect of Molecular Weight, PK, and Valency on Tumor Biodistribution and Efficacy of Antibody-Based Drugs Translational Oncology 6, 562-572 10.1593/tlo.13409
101. Chacko, R., Ventura, J., Zhuang, J., and Thayumanavan, S. (2012) Polymer Nanogels: A Versatile Nanoscopic Drug Delivery Platform Adv. Drug Delivery Rev. 64, 836-851 10.1016/j.addr.2012.02.002
102. Wu, C., Schneider, T., Zeigler, M., Yu, J., Schiro, P. G., Burnham, D. R., McNeill, J. D., and Chiu, D. T. (2010) Bioconjugation of Ultrabright Semiconducting Polymer Dots for Specific Cellular Targeting J. Am. Chem. Soc. 132, 15410-15417 10.1021/ja107196s
103. Xu, H., Aguilar, Z. P., Yang, L., Kuang, M., Duan, H., Xiong, Y., Wei, H., and Wang, A. (2011) Antibody conjugated magnetic iron oxide nanoparticles for cancer cell separation in fresh whole blood Biomaterials 32, 9758-9756 10.1016/j.biomaterials.2011.08.076
104. Nukolova, N. V., Yang, Z., Kim, J. O., Kabanov, A. V., and Bronich, T. K. (2011) Polyelectrolyte nanogels decorated with monoclonal antibody for targeted drug delivery React. Funct. Polym. 71, 315-323 10.1016/j.reactfunctpolym.2010.10.011
105. Chaleawlert-umpon, S. and Pimpha, N. (2012) Preparation of magnetic polymer microspheres with reactive epoxide functional groups for direct immobilization of antibody Colloids Surf., A 414, 66-74 10.1016/j.colsurfa.2012.08.056
106. Kim, C., Kim, S., Oh, W. K., Choi, M., and Jang, J. (2012) Efficient Intracellular Delivery of Camptothecin by Silica/Titania Hollow Nanoparticles Chem.-Eur. J. 18, 4902-4908 10.1002/chem.201200043
107. Traut, R. R., Bollen, A., Sun, T.-T., Hershey, J. W., Sundberg, J., and Pierce, L. R. (1973) Methyl 4-Mercap tobutyrimidate as a Cleavable Cross-Linking Reagent and Its Application to the Escherichia coli 30s Ribosome Biochemistry 12, 3266-3273 10.1021/bi00741a019
108. Hong, H., Yang, K., Zhang, Y., Engle, J. W., Feng, L., Yang, Y., Nayak, T. R., Goel, S., Bean, J., and Theuer, C. P. et al. 2012, In Vivo Targeting and Imaging of Tumor Vasculature with Radiolabeled, Antibody-Conjugated Nanographene ACS Nano 6, 2361-2370 10.1021/nn204625e
109. Chen, F., Hong, H., Zhang, Y., Valdovinos, H. F., Shi, S., Kwon, G. S., Theuer, C. P., Barnhart, T. E., and Cai, W. (2013) In Vivo Tumor Targeting and Image-Guided Drug Delivery with Antibody-Conjugated, Radiolabeled Mesoporous Silica Nanoparticles ACS Nano 7, 9027-9039 10.1021/nn403617j
110. Karra, N., Nassar, T., Ripin, A. N., Schwob, O., Borlak, J., and Benita, S. (2013) Antibody Conjugated PLGA Nanoparticles for Targeted Delivery of Paclitaxel Palmitate: Efficacy and Biofate in a Lung Cancer Mouse Model Small 9, 4221-4236 10.1002/smll.201301417
111. Chan, D. P., Owen, S. C., and Shoichet, M. S. (2013) Double Click- Dual Functionalized Polymeric Micelles with Antibodies and Peptides Bioconjugate Chem. 24, 105-113 10.1021/bc300511a
112. Egli, S., Nussbaumer, M. G., Balasubramanian, V., Chami, M., Bruns, N., Palivan, C., and Meier, W. (2011) Biocompatible Functionalization of Polymersome Surfaces: A New Approach to Surface Immobilization and Cell Targeting Using Polymersomes J. Am. Chem. Soc. 133, 4476-4483 10.1021/ja110275f
113. Agard, N. J., Prescher, J. A., and Bertozzi, C. R. (2004) A Strain-Promoted [3 + 2] Azide-Alkyne Cycloaddition for Covalent Modification of Biomolecules in Living Systems J. Am. Chem. Soc. 126, 15046-15047 10.1021/ja044996f
114. Kotagiri, N., Li, Z., Xu, X., Mondal, S., Nehorai, A., and Achilefu, S. (2014) Antibody Quantum Dot Conjugates Developed via Copper-Free Click Chemistry for Rapid Analysis of Biological Samples Using a Microfluidic Microsphere Array System Bioconjugate Chem. 25, 1272-1281 10.1021/bc500139u
115. Han, H.-S., Devaraj, N. K., Lee, J., Hilderbrand, S. A., Weissleder, R., and Bawendi, M. G. (2010) Development of a Bioorthogonal and Highly Efficient Conjugation Method for Quantum Dots Using Tetrazine-Norbornene Cycloaddition J. Am. Chem. Soc. 132, 7838-7839 10.1021/ja101677r
116. Palanca-Wessels, M. C., Convertine, A. J., Cutler-Strom, R., Booth, G. C., Lee, F., Berguig, G. Y., Stayton, P. S., and Press, O. W. (2011) Anti-CD22 Antibody Targeting of pH-responsive Micelles Enhances Small Interfering RNA Delivery and Gene Silencing in Lymphoma Cells Mol. Ther. 19, 1529-1537 10.1038/mt.2011.104
117. Shuvaev, V. V., Ilies, M. A., Simone, E., Zaitsev, S., Kim, Y., Cai, S., Mahmud, A., Dziubla, T., Muro, S., and Discher, D. E. et al. 2011, Endothelial Targeting of Antibody-Decorated Polymeric Filomicelles ACS Nano 5, 6991-6999 10.1021/nn2015453
118. Hui, J. Z., Zaki, A. A., Cheng, Z., Popik, V., Zhang, H., Luning Prak, E. T., and Tsourkas, A. (2014) Facile Method for the Site-Specific, Covalent Attachment of Full-Length IgG onto Nanoparticles Small 10, 3354-3367 10.1002/smll.201303629
119. Zhang, K., Hao, L., Hurst, S. J., and Mirkin, C. A. (2012) Antibody-Linked Spherical Nucleic Acids for Cellular Targeting J. Am. Chem. Soc. 134, 16488-16491 10.1021/ja306854d